Magazine Article | February 1, 2023

Why Takeda Is Focusing So Much On Plasma-Derived Therapies

Source: Life Science Leader

By Ben Comer, Chief Editor, Life Science Leader

He has nothing against the U.K., his native country, but Giles Platford, president of Takeda’s plasma-derived therapies (PDT) business unit and a member of the company’s executive leadership team, hasn’t lived there in more than 20 years. Over the last two decades, his experiences working in leadership roles across 10 different countries and a handful of biopharmaceutical companies have imbued him with a distinctive perspective on global health and a keen understanding of the challenges many patients face in gaining reliable access to the medications they need. Additionally, Platford’s globe-trotting taught him the business value of diverse viewpoints, which are reflected in his leadership teams, and the importance of partnerships in solving entrenched problems.

access the Magazine Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader